Public Employees Retirement System of Ohio maintained its position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,127 shares of the biotechnology company’s stock at the end of the 2nd quarter. Public Employees Retirement System of Ohio’s holdings in Repligen Corporation were worth $420,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the business. Piedmont Investment Advisors LLC purchased a new stake in shares of Repligen Corporation during the second quarter worth $331,000. Castleark Management LLC purchased a new stake in shares of Repligen Corporation in the second quarter worth $7,592,000. The Manufacturers Life Insurance Company raised its position in shares of Repligen Corporation by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 26,402 shares of the biotechnology company’s stock worth $1,095,000 after buying an additional 106 shares in the last quarter. NBW Capital LLC raised its position in shares of Repligen Corporation by 93.8% in the second quarter. NBW Capital LLC now owns 43,909 shares of the biotechnology company’s stock worth $1,820,000 after buying an additional 21,254 shares in the last quarter. Finally, Alpine Global Management LLC purchased a new stake in shares of Repligen Corporation in the second quarter worth $580,000. Hedge funds and other institutional investors own 96.47% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thestockobserver.com/2017/11/14/public-employees-retirement-system-of-ohio-has-420000-position-in-repligen-corporation-rgen.html.
RGEN has been the topic of a number of recent analyst reports. William Blair initiated coverage on Repligen Corporation in a research report on Friday, July 21st. They issued an “outperform” rating on the stock. BidaskClub downgraded Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research upgraded Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Saturday, August 12th. TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Finally, Jefferies Group LLC restated a “hold” rating and set a $40.00 price target on shares of Repligen Corporation in a research report on Thursday, September 14th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Repligen Corporation has a consensus rating of “Buy” and a consensus target price of $44.67.
Repligen Corporation (NASDAQ:RGEN) opened at $33.53 on Tuesday. Repligen Corporation has a 12 month low of $28.48 and a 12 month high of $46.81. The stock has a market capitalization of $1,512.81, a PE ratio of 59.87, a PEG ratio of 2.31 and a beta of 1.05.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.04. Repligen Corporation had a return on equity of 7.57% and a net margin of 16.93%. The firm had revenue of $36.58 million for the quarter, compared to analysts’ expectations of $35.69 million. During the same period last year, the firm earned $0.08 earnings per share. The company’s revenue for the quarter was up 48.2% compared to the same quarter last year. equities analysts predict that Repligen Corporation will post 0.6 EPS for the current fiscal year.
Repligen Corporation Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.